Evidence map›Paper›PMID 40224423›Full record

ArticleACS omega2025

Optimization and Validation of the Cationization Method for the Fab' Fragment of Antibody Rituximab.

Sandeep Vishwakarma, Suman Ramteke

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sandeep VishwakarmaSchool of Pharmaceutical Sciences, Rajiv Gandhi Proudyogiki Vishwavidyalaya (RGPV), Bhopal 462033, India.ORCID https://orcid.org/0009-0004-9013-6848
Suman RamtekeSchool of Pharmaceutical Sciences, Rajiv Gandhi Proudyogiki Vishwavidyalaya (RGPV), Bhopal 462033, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to optimize and validate a cationization method for the Fab' fragment of antibody rituximab, following the guidelines set by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH). The optimization process involved fragmentation of antibody rituximab into an F(ab)

Identifiers

PMID40224423
PMCPMC11983203

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.